MJA
MJA

Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia

Med J Aust 2012; 196 (10): 638-641. || doi: 10.5694/mja11.10981
  • Margaret E Hellard1,2
  • Rebecca Jenkinson1
  • Peter Higgs3
  • Mark A Stoové1,4
  • Rachel Sacks-Davis1,4
  • Judy Gold1
  • Matthew Hickman5
  • Peter Vickerman6
  • Natasha K Martin5,6

  • 1 Centre for Population Health, Burnet Institute, Melbourne, VIC.
  • 2 Infectious Diseases, Alfred Hospital, Melbourne, VIC.
  • 3 The Kirby Institute, Sydney, NSW.
  • 4 Department of Epidemiology and Preventive Medicine, School of Public Health, Monash University, Melbourne, VIC.
  • 5 School of Social and Community Medicine, University of Bristol, Bristol, UK.
  • 6 Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.

Correspondence: hellard@burnet.edu.au

Acknowledgements: 

We thank Soenke Tremper (General Practice Victoria), Joe Sasadeusz (Royal Melbourne and Alfred Hospitals), Jacqui Richmond (St Vincent’s Hospital), Kate Mellor (St Vincent’s Hospital), Sally von Bibra (Alfred Hospital), Anna Wilkinson (Alfred Hospital) for expert input that informed our parameter estimates.

Competing interests:

No relevant disclosures.

  • 1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-358.
  • 2. Edlin BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room. Int J Drug Policy 2004; 15: 81-91.
  • 3. Australian Government Department of Health and Aged Care. Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners. Canberra: Department of Health and Aged Care and Medicare Australia Pharmaceutical Benefits Scheme, 2001.
  • 4. National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2005–2009. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2010. http://www.med.unsw.edu.au/NCHECRweb.nsf/resources/NSP_Complete2/$file/ANSP.NDR.2005_2009.pdf (accessed Feb 2012).
  • 5. Gidding HF, Topp L, Middleton M, et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997–2006. J Gastroenterol Hepatol 2009; 24: 1648-1654.
  • 6. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123-135.e1-2.
  • 7. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
  • 8. Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010; 110: 228-233.
  • 9. Martin N, Vickerman P, Foster G, et al. Can antiviral therapy for Hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-1144.
  • 10. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011; 274: 58-66.
  • 11. National Institute for Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C: Technology Appraisal Guidance 75 January 2004. London: NICE, 2004. http://www.nice.org.uk/nicemedia/live/11524/32809/32809.pdf (accessed Feb 2012).
  • 12. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
  • 13. Horyniak D, Franklin L, Aitken C, et al. Recruiting injecting drugs users using respondent driven sampling (RDS): experiences from the Melbourne injecting drug user cohort study (MIX). Drug Alcohol Rev 2009; 28 Suppl 1: A30.
  • 14. Reddel SE, Horyniak D, Dietze D, McElwee P. Victorian Drug Trends 2010: findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 58. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2011. http://ndarc.med.unsw.edu.au/resource/victorian-drug-trends-2010-findings-illicit-drug-reporting-system-idrs (accessed Feb 2012).
  • 15. Aitken CK, Lewis J, Tracy SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008; 48: 1746-1752.
  • 16. McCaw R, Moaven L, Locarnini SA, Bowden DS. Hepatitis C virus genotypes in Australia. J Viral Hepat 1997; 4: 351-357.
  • 17. Stoové MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008; 96: 281-285.
  • 18. Gane EJ, Stedman CA, Hyland RH, et al. Once-daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naïve patients with HCV GT2 or GT3 [abstract]. The Liver Meeting 2011. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 Nov 4–8; San Francisco, CA. Hepatology 2011; 54 Suppl 1: 377A.
  • 19. Zeuzem S, Asselah T, Angus PW, et al. High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and PegIFN/ribavirin – the SOUND-C1 study [abstract]. Hepatology 2011; 54 Suppl 1: 249A.
  • 20. McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
  • 21. Welsch C, Zeuzem S. Will interferon-free regimens prevail? Gastroenterology 2012; 142: 1351-1355.
  • 22. Foster GR. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction 2008; 103: 1412-1413.
  • 23. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194: 398-402.
  • 24. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
  • 25. Grebely J, Matthews G, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55: 76-85.
  • 26. Belfiori B, Ciliegi P, Chiodera A, et al. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Dig Liver Dis 2009; 41: 303-307.
  • 27. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 1540-1543.
  • 28. Hellard ME, Wang YH. The role of general practitioners in managing and treating hepatitis C [editorial]. Med J Aust 2009; 191: 523-524.
  • 29. Dennis SM, Zwar N, Griffiths R, et al. Chronic disease management in primary care: from evidence to policy. Med J Aust 2008; 188 (8 Suppl): S53-S56. <MJA full text>
  • 30. Harris MF, Williams AM, Dennis SM, et al. Chronic disease self-management: implementation with and within Australian general practice. Med J Aust 2008; 189 (10 Suppl): S17-S20. <MJA full text>
  • 31. Norman J, Walsh NM, Mugavin J, et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduct J 2008; 5: 8.
  • 32. Australian Institute of Health and Welfare. 2010 National Drug Strategy Household Survey report. Canberra: AIHW, 2011. (AIHW Cat. No. PHE 145; Drug Statistics Series No. 25.) http://www.aihw.gov.au/publication-detail/?id=32212254712 (accessed Feb 2012).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article